CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

ImmunityBio, Inc.

IBRX
$9.31BMid Cap

Next catalyst

Phase 2December 2026

PD-L1 t-haNK

Head and Neck Cancer

Source

Get an email about IBRX's next catalysts

Track ImmunityBio (IBRX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 3 more upcoming events in our data (Phase 2 readout).See the timeline

Catalyst Timeline

5 upcoming, 1 past

Phase 2Next

PD-L1 t-haNK Phase 2 Est. Readout

December 2026~PD-L1 t-haNK25

Estimated primary completion for PD-L1 t-haNK trial (NCT06239220) in Head and Neck Cancer. Topline data typically follows completion by weeks to months.

Source
PDUFA
✓Positive

FDA PDUFA Date ANKTIVA (nogapendekin alfa inbakicept) plus BCG

Jan 6, 2027Nogapendekin alfa inbakicept

For BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease without CIS. sNDA filing. Extracted from SEC filing: EX-99.1

FDA expanded the Anktiva label in bladder cancer; specific details of the expanded indication not provided in the article text.

Source
Phase 2

Anktiva Phase 2 Est. Readout

March 2027~Anktiva40

Estimated primary completion for Anktiva trial (NCT07123727) in Long COVID. Topline data typically follows completion by weeks to months.

Source
Phase 2

N-803 Phase 2 Est. Readout

May 2027~N-80320

Estimated primary completion for N-803 trial (NCT06710288) in Platinum-resistant Ovarian Cancer. Topline data typically follows completion by weeks to months.

Source
Phase 2

CD19 t-haNK- IV Administration Phase 2 Est. Readout

Q2 2027~QCD19 t-haNK- IV Administration20

Estimated primary completion for CD19 t-haNK- IV Administration trial (NCT07125872) in Relapsed B-Cell Non Hodgkin Lymphoma. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaSAN DIEGO
Drug Pipeline

N-803

Phase 3

Pancreatic Cancer

Aldoxorubicin

Phase 3

Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma

N-803 and BCG

Phase 3

Bladder Cancer

Prior failed checkpoint inhibitor

Phase 3

NSCLC Stage IV

INNO-206

Phase 2

Metastatic Soft Tissue Sarcoma

HCW9218

Phase 2

Advanced Pancreatic Carcinoma

CD19 t-haNK- IV Administration

Phase 2

Relapsed B-Cell Non Hodgkin Lymphoma

PD-L1 t-haNK

Phase 2

Head and Neck Cancer

DermaVir

Phase 2

HIV Infection

UI-102

Phase 2

Advanced Cancer

BCG (/instillation) + N-803 (/instillation)

Phase 2

Non-muscle Invasive Bladder Cancer

Nogapendekin alfa inbakicept

Phase 2

Non-small Cell Lung Cancer Stage IV

Anktiva

Phase 2

Long COVID

N-803 + Avelumab + PD-L1 t-haNK

Phase 2

Non-Small Cell Lung Cancer

Intravesical NAI (Cohorts 6-7)

Phase 2

Urothelial Carcinoma

N-803 + Nivolumab

Phase 2

Non-Small Cell Lung Cancer

N-803 + Durvalumab + PD-L1 t-haNK

Phase 2

Non-Small Cell Lung Cancer

Subcutaneous NAI (Cohort 8)

Phase 2

Urothelial Carcinoma

NAI

Phase 2

Head and Neck Cancer

N-803 + Atezolizumab + PD-L1 t-haNK

Phase 2

Non-Small Cell Lung Cancer

Durvalumab (Cohort 4/5)

Phase 2

Urothelial Carcinoma

N-803 + Pembrolizumab + PD-L1 t-haNK

Phase 2

Non-Small Cell Lung Cancer

N-803 + Atezolizumab

Phase 2

Non-Small Cell Lung Cancer

N-803 + Docetaxel + Pembrolizumab

Phase 2

Non-Small Cell Lung Cancer

N-803 + Nivolumab + PD-L1 t-haNK

Phase 2

Non-Small Cell Lung Cancer

Aldoxorubicin HCl

Phase 2

Pancreatic Cancer

N-803 + Pembrolizumab

Phase 2

Non-Small Cell Lung Cancer

N-803 + Avelumab

Phase 2

Non-Small Cell Lung Cancer

N-803 + Docetaxel + Nivolumab

Phase 2

Non-Small Cell Lung Cancer

Bacillus Calmette-Guérin (BCG)

Phase 2

Urothelial Carcinoma

Gemcitabine (GEM)

Phase 2

Advanced Pancreatic Carcinoma

N-803 (IL-15 Superagonist)

Phase 2

Long COVID

N-803 + Durvalumab

Phase 2

Non-Small Cell Lung Cancer

Intravesical Recombinant Mycobacterium (rMBCG)

Phase 2

NMIBC

ALT-803

Phase 2

Acute Myeloid Leukemia

M-CENK

Phase 2

Platinum-resistant Ovarian Cancer

📑
Catalyst DossierPRO
The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.
→

Frequently asked questions

What is in ImmunityBio, Inc.'s drug pipeline?→

CatalystAlert tracks 36 drug candidates in ImmunityBio, Inc.'s (IBRX) pipeline across Phase 3, Phase 2. Its lead program is N-803 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is ImmunityBio, Inc.'s next FDA catalyst?→

ImmunityBio, Inc.'s (IBRX) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track IBRX biotech catalysts?→

Add IBRX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ImmunityBio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply